# EDGAR Filing Document

**Accession Number:** 0001815620
**File Stem:** 0000950170-23-001331
**Filing Date:** 2023-1
**Character Count:** 6275
**Document Hash:** dfd4bb2090ca3bb6c07aa4096cfd499d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-001331.hdr.sgml**: 20230130

**ACCESSION NUMBER**: 0000950170-23-001331

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20230130

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20230130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Opthea Ltd
- **CENTRAL INDEX KEY:** 0001815620
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39621
- **FILM NUMBER:** 23565086

**BUSINESS ADDRESS:**
- **STREET 1:** LEVEL 4
- **STREET 2:** 650 CHAPEL STREET
- **CITY:** SOUTH YARRA, VICTORIA
- **STATE:** C3
- **ZIP:** 3141
- **BUSINESS PHONE:** 61 3 9826 0399

**MAIL ADDRESS:**
- **STREET 1:** LEVEL 4
- **STREET 2:** 650 CHAPEL STREET
- **CITY:** SOUTH YARRA, VICTORIA
- **STATE:** C3
- **ZIP:** 3141

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 6-K** 

------

**REPORT OF FOREIGN ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of January 2023** 

**Commission File No. 001-39621** 

------

**OPTHEA LIMITED**

**(Translation of registrant's name into English)** 

------

**Level 4**

**650 Chapel Street**

**South Yarra, Victoria, 3141**

**Australia**

**(Address of registrant's principal executive office)** 

------

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☒

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ☐

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [<u>Press Release - Opthea to Present at Sequire Biotechnology Conference</u>](opt-ex99_1.htm) |

---

------

**<u>SIGNATURES</u>** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | |
|:---|:---|
| **OPTHEA LIMITED** | **OPTHEA LIMITED** |
| (Registrant) | (Registrant) |
| By: | /s/ Megan Baldwin |
| Name: | Megan Baldwin, Ph.D. |
| Title: | Chief Executive Officer and Managing Director |

---

Date: 1/30/2023

------

## Exhibit 99.1

**Exhibit 99.1**

![img260626642_0.jpg](img260626642_0.jpg)

**ASX, Nasdaq and Media Release**

**January 30, 2023**

**Opthea To Present at Sequire Biotechnology Conference**

**Melbourne, Australia; 30 January, 2023** – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will present at the Sequire Biotechnology Conference being held virtually on February 2, 2023.

Dr. Baldwin will present on Thursday, February 2<sup>nd</sup> at 10:00 am ET (2:00 am AEDT). To access the presentation please register at https://biotech.sequireevents.com.

------

![img260626642_1.jpg](img260626642_1.jpg)

**About Opthea Limited** 

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea's lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

**Inherent risks of Investment in Biotechnology Companies** 

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Company & Media Enquiries:** | &nbsp;&nbsp;**Join our email database to receive program updates:** |
| &nbsp;&nbsp;**U.S.A. & International:** <br>Timothy E Morris CFO<br>Opthea Limited<br>Tel: +1 650-400-6874<br>**Australia:**<br>Rudi Michelson<br>Monsoon Communications<br>Tel: +61 (0) 3 9620 3333<br>**Media:**<br>Hershel Berry<br>Blueprint Life Science Group<br>Tel: +1 415 505 3749<br>hberry@bplifescience.com<br>| &nbsp;&nbsp;Tel: +61 (0) 3 9826 0399<br>Email: info@opthea.com<br>Web: www.opthea.com<br>|

---

------